Reich, K., E. Simpson, R. Langley, R. Warren, A. . Costanzo, H. Saeki, P. Almgren, L. Gjerum, A. Carlsson, M. Gooderham, A. Pinter, M. De Bruin Weller, and A. Blauvelt. “Tralokinumab Demonstrated a Consistent Safety Profile With up to 42 Months of Treatment in Moderate to Severe Atopic Dermatitis: Including Adverse Events of Special Interest”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s143, doi:10.25251/skin.7.supp.143.